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license (http://creativerefinement of pathologic diagnostic criteria. In the present study, the clinical and neuroimaging char-
acteristics of globular glial tauopathy (GGT) were examined to determine whether subtyping accord-
ing to consensus guidelines improves clinicopathologic correlation.
Methods: Confirmed GGT cases (n5 11) were identified from 181 frontotemporal tauopathy cases.
Clinical and neuroimaging details were collected, and cases sub-typed according to the consensus
criteria for GGT diagnosis. Relationships between clinical syndrome and GGT subtype were inves-
tigated.
Results: In total, 11 patients (seven males, four females, mean age 5 67.3 1/2 10.6 years) with
GGT were included. Most, but not all, presented with behavioral variant frontotemporal dementia,
but none had amyotrophic lateral sclerosis. Subtyping of GGT proved to be difficult and did not
improve clinicopathologic correlation.
Discussion: Sub-classification of GGT pathology may be difficult and did not improve clinicopath-
ologic correlation. Better biomarkers of tau pathology are needed.
 2016TheAuthors. PublishedbyElsevier Inc. on behalf of theAlzheimer’sAssociation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Frontotemporal dementia; Globular glial tau; Tauopathy; Clinicopathological correlation1. Introduction
A new dawn of therapeutics in neurodegenerative demen-
tia beckons. Agents are being developed to specifically target
molecular pathologies such as b-amyloid [1–3], a-synuclein
[4], and tau [5]. While encouraging, these developments
pose a significant challenge for clinicians trying to influence
the course of disease in individual patients. In particular, pa-
thologies causing neurodegeneration develop decades before
the onset of symptoms [6,7], meaning that early identification
of specific disease processes will be necessary to delay or
prevent the progression of neurodegeneration. The ability to
select appropriate therapeutic targets, at the right stage of
illness, will be required before effective treatments can be
implemented.thor. Tel.:161 2 9382 2422; Fax:161 2 8244 1950.
urrell@neura.edu.au
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).Although the underlying pathology can be reliably pre-
dicted in some clinical dementia syndromes [8–11],
clinicopathologic correlation remains a challenge in many
others [9,11–16]. For example, TDP-43 and tau pathologies
each account for about half of behavioral frontotemporal de-
mentia (bvFTD) cases but have very similar clinical presen-
tations. Furthermore, the non-Alzheimer’s tauopathies—
diseases associated with the accumulation of phosphorylated
tau inclusions without the presence of ß-amyloid plaques—
have been associated with a wide range of different clinical
phenotypes that include variable combinations of cognitive,
behavioral, and motor impairments [17]. Could more spe-
cific pathologic classification of non-Alzheimer’s tauopa-
thies improve clinicopathological correlation in bvFTD
and other forms of frontotemporal dementia, leading to
more accurate in vivo diagnoses?
The pathologic classification of non-Alzheimer’s tauopa-
thies has been revised extensively over recent years, basedimer’s Association. This is an open access article under the CC BY-NC-ND
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biochemical composition of inclusions containing three-
repeat (3R) and/or four-repeat (4R) tau, as well as the
morphology and the distribution of tau-immunopositive in-
clusions in neurons and glia [18]. Several distinct pathologic
entities are now recognized, but understanding of the rela-
tionships between clinical diagnosis and prognosis remains
limited [9].
One recently described non-Alzheimer’s tauopathy is
globular glial tauopathy (GGT), which is distinguished by
the accumulation of 4R tau in oligodendroglia and astro-
cytes, in addition to deposition in cortical neurones
[19,20]. The distribution of tau inclusions has prompted
the development of a pathologic classification scheme that
proposes three pathologic subtypes of GGT [21]. Type I in-
volves the prefrontal and temporal cortices; type II involves
both the motor cortex and the corticospinal tracts; type III is
defined by the involvement of the prefrontal, temporal, and
motor cortices, and the corticospinal tracts [21]. All three
subtypes are associated with prominent white matter degen-
eration. Although the pathologic criteria acknowledge a
wide variety of clinical diagnoses in patients with GGT, a
more specific relationship between the GGT subtype and
clinical features is proposed. For example, type I cases are
expected to present with frontotemporal dementia (FTD);
type II cases are expected to present with motor neuron dis-
ease (MND) and extrapyramidal deficits (i.e., parkin-
sonism); and type III cases are expected to present with
FTD combined with MND and parkinsonism. Such a close
clinicopathologic correlation between pathologic GGT sub-
type and clinical features remains to be proven.
The present study explored three hypotheses; first, can
GGT cases be easily pathologically sub-typed according to
the scheme outlined in the proposed consensus criteria? Sec-
ond, is each pathologic GGT subtype associated with any
unique clinical, neuropsychological, or neuroradiologic
characteristics that might predict GGT pathology when pa-
tients are assessed in life? Finally, does subtyping of GGT
pathology improve clinicopathologic correlation?2. Methods
2.1. Participants
Neuropathologically confirmed GGT cases (n5 11) were
identified from 181 cases with frontotemporal lobar degen-
eration with tau-immunopositive inclusions (FTLD-tau)
held by the Sydney and Cambridge Brain Banks for inclu-
sion in this study. Both brain banks hold ethics approval
from the Human Research Ethics Committee of South
Eastern Sydney Local Health District and the University of
New South Wales (Sydney), and Addenbrooke’s Hospital
Local Ethics Committee (Cambridge). In addition, both
brain banks comply with the statement of human experimen-
tation issued by the National and Medical Research Council
of Australia. Approval for this specific study was obtainedfrom the University of Sydney Human Research Ethics
Committee.
Patients 1–5 underwent detailed clinical assessment by an
experienced behavioral neurologist (J.R.H. and/or T.H.B.),
as well as formal neuropsychological testing. Patients 1
and 2 were assessed at Frontier, an FTD-specific research
clinic based at Neuroscience Research Australia in Sydney.
Patients 3–5 were assessed in life at the Disorders of Cogni-
tion and Movement Disorders in Cambridge. Patients 6–11
were assessed in life by general neurologists and/or move-
ment disorder specialists. All available records were
searched for pertinent information regarding clinical diagno-
ses and results of neuroimaging.2.2. Neuropathologic classification into FTLD-tau GGT
subtypes
All FTLD-tau cases were reviewed to identify those
meeting criteria for GGT. Historically, GGTwas often incor-
rectly classified pathologically as corticobasal degeneration
(CBD) or progressive supranuclear palsy (PSP) [19,20,22–
24]; therefore, cases previously classified as CBD, PSP, or
as unclassified tauopathy were reassessed after publication
of the GGT criteria [21]. All cases meeting GGT classifica-
tion criteria were selected for this study and sub-classified as
types I–III. The superior frontal, precentral, and inferior
temporal cortices were examined until clear subtype separa-
tion was achieved. The precentral cortex was not available
from two cases (patients 3 and 4). All pathologic reviews
were performed independently and blinded to the clinical
features, by three authors (G.M.H., J.J.K., and S.L.F.) expe-
rienced in the pathologic diagnosis and sub-classification of
tauopathies and GGT. Cases were further sub-typed by two
authors (J.J.K. and S.L.F.). Subsequently, any discordantly
classified cases (n 5 3) were reviewed by both researchers
together until consensus was reached.2.3. Immunohistochemistry
Formalin-fixed paraffin-embedded 10-mm sections were
cut from the superior frontal, precentral, and inferior tempo-
ral cortices. Immunoperoxidase staining using phosphory-
lated tau (clone AT8; mouse; 1:1000; Cat. No. MN1012;
Thermo Scientific Australia, Scoresby, Victoria) was per-
formed using a Discovery DX autostainer (Ventana Medical
Systems, Tuscon, AZ). Sections were counter stained with
Hematoxylin.2.4. Images and figure production
All sections were visualized under a Zeiss Axioskop mi-
croscope (Munchen-Hallbergmoos, Germany), and RGB
images captured using a Zeiss AxioCam HRc camera and
AxioVision 4.7 software. For figure production, only minor
adjustments to brightness and contrast were made using the
levels command in Adobe Photoshop CS6 (San Jose, CA) to
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the microscope.
3. Results
3.1. Patient demographics and clinical features
In total, 11 patients (seven males and four females, mean
age at diagnosis 67.36 10.6 years) with neuropathologically
confirmed GGT were identified from 181 FTLD-tau cases.
The remaining FTLD-tau cases comprised 36 with Pick’s
disease, 43 with corticobasal degeneration, 89 with progres-
sive supranuclear palsy, one case with neurofibrillary tangle
predominant dementia, and one case with argyrophilic grain
disease. Demographic and clinical information on each pa-
tient with GGT is presented in Table 1. Two illustrative cases
are presented below (patients 1 and 2), and additional clin-
ical information on patients 3–5 are presented in
Supplementary Material.
3.2. Patient 1
A 76-year-old woman presented with a 2-year history of
progressive speech disturbance. The speech became hesi-
tant, with slurring and sound distortion. Early in the course
of the illness, she developed “yes”/“no” confusion, produc-
ing these responses either randomly or inappropriately.
Initially, reading and writing abilities were relatively pre-
served, as was comprehension. Over time, she demonstrated
reduced motivation, rigid behavior, emotional blunting, and
her self-care deteriorated. The patient had an identical twin
who was fit and well. There was no family history of neuro-
degenerative disease.
When assessed 4 years after the initial diagnosis, the
patient had severe dysarthria. Repetition of simple words
was intact, but impairment was noted with more complex
words such as “hippopotamus”, “caterpillar”, or “chrysan-Table 1
Clinical presentation and globular glial tauopathy (GGT) subtype
Patient
Age at
diagnosis (y)
Duration of
illness at
death (y)* Gender Clinical diagnosis
1 76 7 Female PNFA
2 56 4 Male bvFTD
3 61 12 Male bvFTD
(right-temporal va
4 71 17 Male bvFTD
5 65 8 Male bvFTD
6 69 5 Male bvFTD
7 72 9 Female bvFTD
8 54 9 Female bvFTD
9 86 3 Female AD
10 77 2 Male CBS
11 71 4 Male MSA
NOTE. Of 11 patients with GGT, seven presented with behavioral variant fronto
sia (PNFA), one with an amnestic Alzheimer’s-like syndrome, one with corticoba
*For patients 1–5, the duration of illness is calculated as the time from symptom
as the time from diagnosis to death.themum”. Dysarthria hampered assessment of anomia, but
single word comprehension was preserved. Marked dysgra-
phia, with gross spelling errors, was noted.
In addition to dysarthria, the patient demonstrated severe
orobuccal apraxia, but therewas no tonguewasting or fascic-
ulation. Mild rigidity of the right upper limb was noted, but
there were no other features of parkinsonism and no other
motor signs. Limb apraxia was present bilaterally and sym-
metrically, with impaired miming of object use and gestures.
On neuropsychological screening, the patient scored 41
of 100 on the Addenbrooke’s Cognitive Assessment—
Revised (ACE-R, Normal . 88/100). She lost points in all
cognitive domains, but especially on memory (1/26) and ver-
bal fluency (0/14). Formal neuropsychological testing was
limited because of language deficits, but impaired single
word repetition and object naming was confirmed. A mag-
netic resonance imaging (MRI) of the brain revealed mild
peri-insular atrophy on the left, but frontal, temporal, and pa-
rietal lobe volumes were preserved. The patient died 7 years
after diagnosis.3.3. Patient 2
A 56-year-old man presented with a 3-year history of
behavioral changes and language impairment. Social with-
drawal and disorganization at work were early symptoms,
but disinhibition soon developed and became more promi-
nent. His table manners deteriorated, and he often licked
plates and bowls at meals, even when dining with friends
in restaurants. He began barking at dogs and tweeting at
birds in public. His behavior became stereotyped and ritual-
istic, and he developed a sweet food preference. Over time,
his self-care declined, and he had to be persuaded to change
his clothes. He defecated on the bedroom floor on several oc-
casions. Cognitively, the patient’s vocabulary diminished
and his participation in conversations declined markedly.Pathologic
subtype
Affected brain
regions on MRI
Symmetrical
atrophy on MRI
III Frontal, temporal 1
III Frontal, temporal, parietal 1
riant)
I Frontal, temporal 2
III Frontal, temporal, parietal 2
I Frontal, temporal, parietal 2
III Frontal, temporal, parietal 1
I Frontal, temporal 1
III Not available N/A
III Not available N/A
II Frontal, temporal, parietal 2
II Frontal, temporal, parietal 1
temporal dementia (bvFTD), one presented with progressive nonfluent apha-
sal syndrome, and one with multiple system atrophy.
onset to death, whereas for patients 6–11, the duration of illness is calculated
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grasp of current events. Clear word finding difficulty was
present in spontaneous speech, but there were no phonolog-
ical or syntactic errors. Object naming and single word
comprehension were very poor, but singleword and sentence
repetition were intact. Limb examination revealed no motor
deficits, parkinsonism, or limb apraxia.
The patient scored 50 of 100 points on the ACE-R
(Normal. 88/100), losing most points on the verbal fluency,
language, and memory components. Formal testing demon-
strated marked executive impairment, impaired object
naming, and impaired word and object knowledge. Syntactic
comprehension was also impaired, but visuospatial ability
appeared to be preserved.
Magnetic resonance imaging of the brain revealed
marked frontal and temporal atrophy (See Fig. 1). The ante-
rior poles and mesial aspects of the temporal lobes were
affected bilaterally, with no significant asymmetry. The
dorsolateral prefrontal, interhemispheric, and orbitofrontal
cortices were affected bilaterally, again with no particular
asymmetry. The patient declined quickly and died only
1 year after the initial assessment.Fig. 1. MRI appearances of globular glial tauopathy (GGT). T1 coronal MRI from
matched control subject (third row). First row: Sequences taken through the ante
patient 2. The anterior poles and mesial aspects of the temporal lobes were affected
hemispheric, and orbitofrontal cortices were affected bilaterally, again with no part
atrophy is appreciated in a case of pathologically confirmed non-GGT FTLD tauo
volumes (G–I).3.4. Patients 3–11
The clinical diagnosis of cases 3–11 can be seen in
Table 1. Overall, seven patients were diagnosed clinically
with bvFTD. Another case presented with an amnestic syn-
drome, but no significant behavioral disturbances, and was
diagnosed clinically with probable Alzheimer’s disease.
One case had a progressive nonfluent aphasia (PNFA)
pattern. Two cases presented with movement disorder syn-
dromes; one with corticobasal syndrome (CBS) and one
with multiple system atrophy (MSA). No GGT cases were
diagnosed with MND, either in isolation or in combination
with dementia. Of the seven bvFTD patients, two had coex-
isting memory deficits, and two had coexisting language
impairment. The two patients who presented with CBS
and MSA were not demented. Parkinsonism was detected
in two further patients who presented with behavioral and
cognitive impairment. Antemortem MRI results were avail-
able on nine cases (See Table 1). Frontal and temporal atro-
phy were present in all cases, with additional parietal
atrophy in six of them. Asymmetrical atrophy was reported
in four cases (three left-hemisphere predominant).patient 2 (first row), a non-GGT FTLD tauopathy (second row), and an age-
rior temporal (A), mid-temporal (B), and posterior temporal (C) regions of
bilaterally, with no significant asymmetry. The dorsolateral prefrontal, inter-
icular asymmetry. Second row: A similar pattern of frontal and temporal lobe
pathy (D–F). Third row: a control subject with normal frontal and temporal
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All cases had AT8-immunoreactive globular astrocytic
and oligodendroglial inclusions in the gray and white matter
(Fig. 2A, B, E, F, I, J). All globular astrocytic inclusions were
located in proximal astrocytic processes, although their
morphology was heterogeneous between GGT subtypes
(Fig. 2C, G, K). In contrast, the morphology of globular
oligodendroglial inclusions was similar between GGT sub-Fig. 2. Distribution and morphology of astrocytic and oligodendroglial pathology
each column are taken from the same case (A–D superior frontal cortex in GGT typ
type III), and all sections are counterstained with hematoxylin. Scale bar in A 5
Abbreviations: GAI, globular astrocytic inclusion; GOI, globular oligodendrogliatypes (Fig. 2D, H, L). The distribution of both types of inclu-
sions was heterogeneous between cortices and between the
gray and white matter (Fig. 2A, B, E, F, I, J).
Using the classification scheme proposed by Ahmed
et al 2013, three cases were classified as type I, two cases
as type II and six cases as type III. Type I cases had globular
glial inclusions predominantly in thewhite matter underlying
the superior frontal and inferior temporal cortices, with fewer
inclusions in the associated gray matter (Fig. 2A, B). In twoin each globular glial tauopathy (GGT) subtype. Representative images in
e I; E–H precentral cortex in GGT type II; I–L superior frontal cortex in GGT
200 mm (applies to B, E, F, I, J); 20 mm in C (applies to D, G, H, K, L).
l inclusion.
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gray and white matter of the precentral cortex. A third case
was classified as type I, although the precentral cortex was
unavailable (patient 3), because of the widespread distribu-
tion of globular glial inclusions which predominantly
involved the white matter of the superior frontal and inferior
temporal cortices. Two of the type I cases were diagnosed
clinically with bvFTD, and a third was classified as the
right-temporal variant of bvFTD.
In type II cases, the demarcation of gray and white matter
AT8-immunopositive pathology was less clear, with a
similar prevalence of AT8-immunopositive globular glial in-
clusions in both regions. In both type II cases, globular glial
inclusions predominantly occurred in the precentral cortex
(Fig. 2E, F). Both type II cases presented with parkinsonian
syndromes (one with MSA and another with CBS), but
neither had obvious pyramidal signs or other clinical fea-
tures of MND.
Type III cases had AT8-immunopositive globular glial in-
clusions in both gray and white matter in all cortical regions
examined (Fig. 2I, J), although the distribution was hetero-
geneous between cases. The precentral cortex was unavai-
lable in one type III case (patient 4), and emphasis was
placed on the prevalence of globular glial inclusions in
both the gray and white matter of the superior frontal and
inferior temporal cortices. One type III case (patient 1, See
patient demographics and clinical features) was diagnosed
clinically with PNFA, but the remainder of type III cases,
including patient 2, was diagnosed with bvFTD.
Five GGT cases had less AT8-immunopositive pathology
(patients 1, 4, 7, 9, and 10) and were difficult to further sub-
type and in three of these cases (patients 4, 9, and 10), the
researchers were not in agreement. On revision of these
cases, consensus was achieved with careful consideration
of the distribution between cortices followed by the severity
of gray versus white matter pathology.4. Discussion
The present study demonstrated that although the appli-
cation of the GGT criteria was achievable, sub-
classification of cases into types I–III proved problematic,
even for experts in the classification of non-Alzheimer’s
tauopathies. Clinically, GGT patients presented with a vari-
ety of different, but overlapping, syndromes. No distinctive
clinical syndrome or radiologic characteristic predicted
GGT in life. Furthermore, subtyping of GGT into the three
subtypes proposed by the consensus criteria did not improve
clinicopathologic correlation. The results of this study are
important, because they call into question the clinical utility
of pathologic subtyping GGT, and indeed, the subtyping of
non-Alzheimer’s tauopathies more generally. Conversely,
the results suggest that more sophisticated clinical phenotyp-
ing may not reliably predict underlying GGT or other non-
Alzheimer’s tauopathies. Finally, given that the analysis of
clinical symptoms and signs will never be useful in detectingasymptomatic or at risk individuals, the results emphasize
the need for better biomarkers of tau pathology.
Before discussing the details of the present study in more
depth, it is important to consider several potential limita-
tions. First, although the current cohort of GGT represents
one of the largest yet assembled, the pathology is rare, and
the number of cases available for inclusion was relatively
low, despite the availability of a large number of pathologi-
cally confirmed non-Alzheimer’s tauopathies. The included
cases were collected over a long period of time and from
multiple sources; this limited the quantity and uniformity
of the available clinical data, making detailed clinicopatho-
logic correlation, and statistical analyses, challenging. In
particular, it is possible that subtle and clinically insignifi-
cant pyramidal signs were underappreciated in the current
cohort. Nonetheless, half of the cases, including the two
illustrative examples, were seen in specialist clinics and un-
derwent detailed evaluation, providing useful insights.
Finally, the precentral cortex was unavailable for two of
the cases making subtyping of those particular cases prob-
lematic. Ultimately, larger cohorts of GGT patients will be
required for relationships between clinical phenotypes and
GGT subtypes to be established definitively.
Fundamental application of the diagnostic criteria to
identify GGTwas straight-forward, but further classification
into subtypes I–III was more difficult, especially in cases
with less prominent pathology. As demonstrated by Brain-
Net Europe, consensus is often difficult in neuropathologic
diagnosis and further studies taking into account inter-rater
reliability are necessary to ensure that GGT subtyping is
easily reproducible. However, given that pathologic subtyp-
ing of GGT did not appear to improve clinicopathologic cor-
relation in the present study, differentiation of GGT from
other non-Alzheimer’s tauopathies [18] is likely to be
more important for diagnostic purposes.
The previous literature on GGT is based on single case re-
ports [22,23,25–29] or small case series [19,20,24,30–32];
only one previous study of six cases [32] has classified cases
according to the proposed subtyping scheme (I–III). Awide
variety of clinical phenotypes have been described, but
bvFTD [19,20,22,25,26,32] and PNFA [23,27,29,32]
presentations are most commonly reported. Some cases
have presented with a non-FTD clinical syndrome [24,32].
Indeed, a large proportion of patients in one case series
were diagnosed clinically with an atypical PSP phenotype
on the basis of rigidity and symmetrical parkinsonism
[24]. In terms of motor symptoms and signs, parkinsonism
is frequently reported, but it can be symmetrical or asymmet-
rical [20,24,26,28,30–32]. Pyramidal tract signs appear to be
a common, but inconsistent occurrence [19,20,24,28,31,32],
with only a couple of studies reporting clinical or
neurophysiological evidence of anterior horn cell
involvement [31,32]. One very recent report [30] describes
severe anterior temporal atrophy in association with the
right-temporal variant of bvFTD (right anterior temporal at-
rophy) and semantic dementia (left anterior temporal
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described elsewhere.
In the present study, most cases were diagnosed clinically
as bvFTD, with one diagnosed as PNFA and two others with
atypical parkinsonian syndromes. Unlike other published
cases [19,20,24,27,28,31,32] and despite assessments by
clinicians (J.R.H. and T.H.B.) with a long-standing interest
in MND and FTD-MND, none of our cases had MND or
even a predominance of pyramidal signs. None presented
with semantic dementia, although one of the bvFTD cases
had prominent right-temporal lobe involvement. At a clin-
ical level, the GGT cases were indistinguishable from other
bvFTD or atypical parkinsonian syndromes and no distinc-
tive clinical signature of this disease emerged.
Subtyping of GGT pathology does not appear to correlate
with any particular clinical phenotype. Only one previous
case series subtyped GGT cases according to the consensus
criteria [32]. Six cases were reported, but only three pre-
sented with clinical features consistent with the proposed
pathologic subtype. For example, patient 2 (type I) in that se-
ries presented with cognitive symptoms but not FTD. Patient
3 (type III) presented with bvFTD, but no features of MND.
Patient 6 (type III) presented with parkinsonism and cogni-
tive symptoms but no behavioral changes or features of
MND. Consistent with these findings, GGT subtype corre-
lated poorly with the clinical presentation in the present
study. Although the two type II cases were diagnosed with
atypical parkinsonian syndromes, neither had features of
MND as predicted by the consensus criteria. Of the remain-
ing cases, all of whom presented with bvFTD, PNFA, or an
amnestic syndrome, six were sub-classified as type III and
three as type I, despite a general absence of MND features
and otherwise similar clinical presentations.
If clinical features are unreliable in the detection of GGT
and other non-Alzheimer’s tauopathies, how can an early
and accurate diagnosis of these diseases be made? One of
the most promising developments has been the refinement
of tau positron emission tomography (PET) ligands. A num-
ber of different tau PET ligands have been developed over
the last decade, although several challenges remain
[33,34]. In particular, many of the early tau ligands were
designed to bind to ß-pleated sheets [33–35], rather than
tau aggregates per se, resulting in nonspecific binding to
tau and ß-amyloid; newer compounds are more specific for
tau. Furthermore, isoform predominance (i.e., 3-R or 4-R
tau), variability in conformation and post-translational mod-
ifications of tau, as well as variability in aggregate ultrastruc-
ture may influence binding of potential diagnostic ligands
[33–36]. Whether such characteristics vary across the
range of non-Alzheimer’s tauopathies remains unknown.
Encouragingly, ligands may be capable of demonstrating
distribution and spread of tau pathology, suggesting
potential for diagnosis of specific non-Alzheimer’s
tauopathies [37].
A new therapeutic era based around manipulation of spe-
cific molecular pathologies shows genuine promise for thetreatment of neurodegenerative diseases, but diagnostic and
prognostic markers of specific disease entities need to be
developed. In the case of GGT, a rare but potentially distinct
non-Alzheimer’s tauopathy, a clear clinicopathologic correla-
tion has not yet emerged, despite the development of
well-considered pathologic criteria. Based on the results of
the present study, subtyping of GGT cases as proposed by
the consensus criteria is difficult and may not improve clini-
copathologic correlation. Longitudinal studies with detailed
clinical, neuropsychological, and neuroradiologic character-
ization, as well as pathologic confirmation, are required to
determine if any sensitive and specific markers of GGT, and
non-Alzheimer’s tauopathies in general, exist.
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1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and
citations within articles. Key words were globular
glial tau (GGT) and frontotemporal dementia.
2. Interpretation: Our findings show that the subtyping
of GGT according to the consensus guidelines is
difficult and may not improve clinicopathologic cor-
relation.
3. Future directions: Future studies should aim to (1) re-
assess the value of GGT subtyping with larger co-
horts; (2) determine whether biomarkers of tau
pathology (e.g., tau PET ligands) are more useful
diagnostically.
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